Idioma:

Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial

Passardi, A. ; Nanni, O. ; Tassinari, D. ; Turci, D. ; Cavanna, L. ; Fontana, A. ; Ruscelli, S. ; Mucciarini, C. ; Lorusso, V. ; Ragazzini, A. ; Frassineti, G.L. ; Amadori, D.

Annals of oncology, 2015-06, Vol.26 (6), p.1201-1207 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial
Autor: Passardi, A. ; Nanni, O. ; Tassinari, D. ; Turci, D. ; Cavanna, L. ; Fontana, A. ; Ruscelli, S. ; Mucciarini, C. ; Lorusso, V. ; Ragazzini, A. ; Frassineti, G.L. ; Amadori, D.
Assuntos: Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors - adverse effects ; Angiogenesis Inhibitors - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; bevacizumab ; Bevacizumab - adverse effects ; Bevacizumab - therapeutic use ; Camptothecin - adverse effects ; Camptothecin - analogs & derivatives ; Camptothecin - therapeutic use ; chemotherapy ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - pathology ; Disease Progression ; Disease-Free Survival ; Female ; Fluorouracil - adverse effects ; Fluorouracil - therapeutic use ; Humans ; Italy ; Kaplan-Meier Estimate ; Leucovorin - adverse effects ; Leucovorin - therapeutic use ; Male ; metastatic colorectal cancer ; Middle Aged ; Neoplasm Metastasis ; Organoplatinum Compounds - adverse effects ; Organoplatinum Compounds - therapeutic use ; Proportional Hazards Models ; randomized clinical trial ; Risk Factors ; Time Factors ; Treatment Outcome
É parte de: Annals of oncology, 2015-06, Vol.26 (6), p.1201-1207
Descrição: We report the results from a first-line phase III randomized clinical trial on metastatic colorectal cancer (mCRC) aimed at evaluating the effectiveness of adding bevacizumab (B) to standard first-line chemotherapy (CT). mCRC patients were randomized to receive first-line CT (FOLFIRI or FOLFOX4) plus B (arm A) or CT only (arm B). The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), response rate (ORR) and safety. Three hundred and fifty patients and 310 events were required to have an 80% statistical power to detect a difference in PFS between the groups. Between November 2007 and March 2012, 376 patients were randomized. About 60% of patients received FOLFOX4 and 40% FOLFIRI. After a median follow-up of 36 months, 343 progressions and 275 deaths had been observed in the overall population. The median PFS was 9.6 [95% confidence interval (CI) 8.2–10.3] and 8.4 (95% CI 7.2–9.0) months for arms A and B, respectively, with a hazard ratio of 0.86 (95% CI 0.70–1.07; P = 0.182). No statistically significant differences in OS or ORR were observed. B-containing regimens were associated with more frequent hypertension, bleeding, proteinuria and asthenia. The addition of B to standard first-line CT for mCRC did not provide a benefit in terms of PFS, OS or ORR. Further research is warranted to better identify the target population. NCT01878422.
Editor: England: Elsevier Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Resultado 1 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial

Passardi, A. ; Nanni, O. ; Tassinari, D. ; Turci, D. ; Cavanna, L. ; Fontana, A. ; Ruscelli, S. ; Mucciarini, C. ; Lorusso, V. ; Ragazzini, A. ; Frassineti, G.L. ; Amadori, D.

England: Elsevier Ltd

Buscando em bases de dados remotas. Favor aguardar.